Federal Government Relations

 The 2010 BIO Legislative Day Fly-In will take place on April 13-14, 2010. Our annual fly-in events provide the opportunity for the BIO members to meet with Congress and to advocate BIO’s legislative agenda. Biotech executives from across the nation are welcomed and encouraged to participate.

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Letters, Testimony & Comments

December 18 2012
BIO President and CEO Jim Greenwood wrote a letter in support of H.R. 6672, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2012, sponsored and championed by Chairman Mike Rogers (R-MI).
October 18 2012
A keynote Address by James C. Greenwood, President & CEO of BIO, to RETECH 2012 in Washington, DC on October 18, 2012.
June 28 2012
The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to enhance IP protection abroad for U.S. interests.
June 21 2012
Senators Sanders and Boxer have introduced an amendment that will result in costly and extreme food labeling requirements.
June 21 2012
BIO, which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations around the world, strongly opposes the Sanders-Boxer Amendment (#2310) to the Farm Bill.

Press Releases

May 16 2013
H.R. 701 sets a deadline to complete rule-making on Regulation A reforms.
May 15 2013
H.R. 1952 will stimulate trading for small public companies.
April 16 2013
Bill would allow emerging biotech companies to maintain a working relationship with their independent auditor.
March 5 2013
On March 4, 2013, the U.S. House of Representatives passed PAHPRA by a vote of 370-28.
February 28 2013
BIO lauds the Senate for passing H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), yesterday by a unanimous vote.